Summary of the technology
Novel pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. These novel pentose derivatives have beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising them.
Project ID : 12-2006-177
Description of the technology
Novel pentose derivatives for treating hyperglycemia
Diabetes drugs, hyperglycemia
Patent granted in US and pending in EU
Proof of concept in animal models, acute toxicology performed
Global diabetes drugs treatment market was valued at $15 billion in 2005
Existing anti-hyperglycemic drugs that ameliorate insulin secretion and action have a relatively high rate of failure.
- There is an intensive worldwide effort to develop a new generation of anti-hyperglycemic drugs that mimic insulin action even in the total absence of insulin.
- This novel approach is based on the discovery that some pentoses and their derivatives augment glucose transport in skeletal muscle cells in a non-insulin-dependent manner.
These potential antihyperglycemic drugs may reduce high blood glucose levels in Type-2 diabetic subjects by augmenting the rate of peripheral glucose disposal in insulin sensitive tissues (i.e., skeletal muscles).
- Increases rate of cellular glucose transport and utilization
- Improves peripheral glucose disposal
- Treats daily glucose fluctuations
- Reduces dosage of anti-diabetic medication needed for diabetes treatment
- Pharmacokinetic studies of the drug delivery system using larger number of volunteers
- In vitro and in vivo evaluation of current and planned formulations of the prototype compounds
- Diabetes affects over 180 million people worldwide and the market is growing at three times the rate of population growth. Poor control of blood sugar results in severe long-term complications such as kidney failure, nerve damage, blindness, amputation and cardiovascular disease.
- In recent years, there has been a change in the treatment of hyperglycemia in the United States away from monotherapy with oral antihyperglycemic drugs toward combination therapies to improve glycemic control and reduce the risk of hypoglycemic symptoms in treated individuals.